We will agree to disagree here.
The CEO's words are not what guided my opinions, and I have not bought yet.
I am simply saying, this press release regarding phase II of study doesn't really tell us much.
It was 40 patients, and they deemed it ineffective because the placebo group also had positive results. Not only was it only 40 patients, but the dose ranges were also very limited given how safe the drug appears to be. This kind of report could easily be forgotten when the good news comes out... This trial very well could have attracted pharma interest that we don't know about .. etc, laymen opinion doesn't matter much. Do you work for a major pharm company?
Where do you note my lack of knowledge on the science?
Regardless, my opinion really comes down to the millions of dollars spent buying up shares, at both high and low price levels. Buying in chunks of that size tells me something. When I see a buy worth 10-20 million dollars, it does tell me something. Those with multiple millions of dollars, don't just gamble it on a tanking pharm stock.
Time will tell.
News 
Market Data 
Discover 
